Prerpints.org logo
Preprint
Review

Effects of Caffeine on Blood Platelets and the Cardiovascular System through Adenosine Receptors

This version is not peer-reviewed.

Submitted:

26 June 2024

Posted:

26 June 2024

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract
Caffeine is the most popular and widely-consumed behaviourally-active substance in the world. This review focuses on the influence of caffeine on the cardiovascular system, with a special focus on blood platelets. For many years, caffeine was thought to have a negative effect on the cardiovascular system mainly due to increasing blood pressure. However, more recent data suggests that habitual caffeine consumption may reduce the risk of cardiovascular disease and hypertension. This could be a significant finding as cardiovascular disease is the leading cause of death worldwide. Caffeine is known to inhibit A1 adenosine receptors, through which it is believed to modulate inter alia coronary blood flow, total peripheral resistance, diuresis and heart rate. Although few publications have reported the effects of caffeine on platelet function, it seems reasonable to conclude that caffeine has antiplatelet activity. Platelet activation is known to play a crucial role in the development of arterial thrombotic diseases such as coronary heart disease and stroke, and hence there is a need to develop novel platelet inhibitors. One promising strategy to develop effective antiplatelet therapy involves targeting multiple pathways of platelet activation. Therefore, this review also examines the concept of dual antiplatelet therapy and the potential benefits associated with the therapeutic use of combined P2Y12 antagonists and adenosine receptor agonists in cardioprotection.
Keywords: 
adenosine receptors
;  
antiplatelet therapy
;  
caffeine
;  
cardiovascular system
Subject: 
Biology and Life Sciences  -   Biochemistry and Molecular Biology

1. Introduction

Caffeine (1,3,7 trimethylxanthine) is one of the most frequently-consumed behaviourally-active substances in the world. It is commonly found in coffee, tea, various soft and energy drinks, and chocolate [1]. The richest source is coffee, one of the most popular beverages in the world [2,3,4]. Global coffee consumption in 2021/2022 is estimated to be 175.6 million bags, with a bag containing 60 kg of coffee [5]. Drinking coffee has become a daily habit for many people, with Americans consuming around 517 million cups of coffee every day [6] and the mean daily consumption per capita being two to three cups of coffee [6].
The cardiovascular system is composed of the heart, blood vessels and blood, with the heart being arguably the most important. The blood vessels form a network of arteries, veins and capillaries, whose main function is to carry blood. The primary role of blood is of course to carry oxygen and other nutrients to various organs, and carbon dioxide to the lungs for removal.
Cardiovascular disease (CVD), a term referring to all diseases that affect the circulatory system, including the heart and blood vessels, is known to be the leading cause of death worldwide [7], with more than 500 million people suffering from heart and coronary disease [8]. More importantly, this trend is increasing [9], and 20.5 million deaths were caused by cardiovascular disease in 2021 [8]. Several socioeconomic, metabolic, behavioural and environmental risk factors have been identified for CVD, including hypertension, tobacco use, excessive alcohol consumption, unhealthy diet, physical inactivity, diabetes and obesity together with the effects of air pollution, kidney disease and stress [8,9]. However, although the number of deaths from CVD has increased worldwide, the age-standardised death rate appears to have fallen by a one-third over the last three decades [8].
There is no doubt that caffeine affects the human organism. It is believed to exert its influence via the activity of adenosine receptors (AR), ryanodine receptors (RyRs) and GABA receptors, or by inhibiting phosphodiesterase (PDE) [10]. For many years, caffeine consumption has been believed to have a negative effect on the cardiovascular system [11]; however, recent data suggests that coffee consumption may in fact have several positive effects on human health [12,13].
It has been proposed that caffeine exerts most of its biological effects via adenosine receptors [14]. As such, the aim of the present review is to examine the effects of caffeine on blood platelets and the cardiovascular system via ARs. It is also assumed that coffee is the richest source of caffeine and most popular caffeinated beverage in the world. The interaction between caffeine and the cardiovascular system is of particular importance considering the high mortality associated with CVD, and our findings may indicate areas for possible future research.

2. Characteristics of Caffeine

2.1. General Information

Caffeine (1,3,7-trimethylxanthine) is a purine alkaloid, and the most widely-consumed behavioural stimulant across the globe [10]. In its pure state, it exists as a white, odourless, fat- and water-soluble powder [10,15]. It is known to occur naturally in over sixty plant species, although it is primarily found in coffee beans, tea leaves and cocoa beans, as well as guarana berries and kola nuts [10,15,16]. Caffeine itself was first discovered in tea (Camellia sinensis L.) and coffee (Coffea arabica L.) in 1820 [17]. Currently, the richest and most popular natural source of caffeine is believed to be coffee. It is obtained from the roasted beans of Coffea arabica L. (Arabica coffee) and Coffea canephora Pierre ex Froehner (Robusta coffee), both of which belong to the Rubiaceae family.

2.2. Metabolism of Caffeine in Humans

In humans, almost 99% of caffeine is absorbed within 45 minutes of ingestion, mostly in the gastrointestinal tract [10,18]. The absorption process may be affected by various factors, including pH or route of administration [19]. Following oral intake, the maximum plasma concentration is achieved at 15-120 minutes [10,15,18]. It typically takes 45-60 minutes for caffeine to produce its effect, although subsequent food intake may delay this [10,15]. Caffeine has a metabolic half-life of approximately three to five hours and can cross the blood-brain barrier; it can also enter various bodily fluids including serum, milk, saliva, and semen [10,15,19,20].
Most caffeine is metabolised in the liver (99%), and this process mediated by the cytochrome P450 oxidase enzyme system [10,21]. In the first step, the caffeine is subjected to 3-demethylation by cytochrome P450 isoform 1A2 (CYP1A2), leading to the formation of its primary metabolite 1,7-dimethylxanthine (paraxanthine) [10,19]. Following this, the paraxanthine undergoes 1- and 7-demethylation, also catalysed by CYP1A2, which consequently leads to the formation of 3,7-dimethylxanthine (theobromine) and 1,3-dimethylxanthine (theophylline) [10,19]. A small proportion of the ingested caffeine (0.5-4.0%) is excreted in urine and bile without undergoing any change [20,22].
Caffeine metabolism is known to be influenced by individual variations in CYP1A2 activity [23], which can range from 5 to 15-fold in healthy individuals in response to various environmental and genetic factors [24]. A key factor believed to induce CYP1A2 activity is the consumption of caffeinated products, particularly coffee [22,24]. Additionally, various lifestyles have been linked to an increase in CYP1A2 activity; for example, higher coffee consumption has been noted among smokers [25], and the use of oral contraceptives, pregnancy, obesity, or alcohol consumption, have been found to affect caffeine metabolism [22].
Genetic factors also play an important role in caffeine metabolism [23], with two genes being associated with this process: CYP1A2 and ADORA2A [10]. A single nucleotide polymorphism (SNP) within CYP1A2 (-163C > A; rs762551) has been reported to exert an impact on CYP1A2 induction [10,26]; it appears to differentiate between "fast" (AA genotype) and "slow" (AC or CC genotype) caffeine metabolizers [10,27]. The rs5751876 SNP in the ADORA2A gene [28] also influences the response to caffeine, with the TT genotype indicating "high responders to caffeine" and the CC/CT genotype indicating "low responders to caffeine" [27]. These terms denote individual sensitivity to caffeine and thus variability in caffeine metabolism [10].
Preprints 110388 g001
Figure 1. Metabolism of caffeine leading to the formation of the main metabolites: paraxanthine, theophylline and theobromine. Cytochrome P450 isoform 1A2 (CYP1A2) is responsible for 3-demethylation of the caffeine, leading to the formation of 1,7-dimethylxanthine (paraxanthine). It also facilitates the 1- and 7-demethylation of caffeine, which results in the formation of 3,7-dimethylxanthine (theobromine) and 1,3-dimethylxanthine (theophylline).
Figure 1. Metabolism of caffeine leading to the formation of the main metabolites: paraxanthine, theophylline and theobromine. Cytochrome P450 isoform 1A2 (CYP1A2) is responsible for 3-demethylation of the caffeine, leading to the formation of 1,7-dimethylxanthine (paraxanthine). It also facilitates the 1- and 7-demethylation of caffeine, which results in the formation of 3,7-dimethylxanthine (theobromine) and 1,3-dimethylxanthine (theophylline).
Preprints 110388 g001

2.3. Biological Effects of Caffeine

Caffeine affects the cardiovascular, nervous, immune, respiratory, renal, digestive, and musculoskeletal systems [10,18,29]. Both caffeine and its metabolites have the ability to modify lipid and glucose metabolism [30,31]. Caffeine is known to affect the sympathetic nervous system resulting in the secretion of epinephrine and norepinephrine [10].
Caffeine also stimulates the central nervous system and enhances hormonal secretion [32]. It elevates neurotransmitter levels in the brain, resulting in behavioural and neurochemical changes [32], and has been shown to possess neuroprotective properties [19]. Moreover, caffeine plays a crucial role in inflammatory processes in a dose-dependent manner [33]. It appears that minimal caffeine levels could have negative effects, while higher concentrations may reduce inflammatory biomarkers and also activate anti-inflammatory mechanisms [10]. Furthermore, experimental studies suggest that caffeine may play a role in the antioxidant properties of coffee [32].
Caffeine can influence cells by blocking adenosine receptors, releasing stored intracellular calcium, and inhibiting phosphodiesterases (PDEs) [18]. It can block all adenosine receptors, in particular A1R and A2AR [10,16]. It is worth noting that while caffeine can block adenosine receptors at low doses, higher levels are needed for the two other mechanisms [16]. Caffeine can also induce calcium release from the endoplasmic reticulum [10] by binding to ryanodine receptors (RyRs) [34]; this also inhibits calcium reuptake [35]. As a result of these processes, caffeine can enhance contractility during submaximal contractions in both habitual and non-habitual caffeine consumers [16]. Finally, it is also a non-selective competitive inhibitor of phosphodiesterases, which can increase cellular cAMP concentration [10]. The accumulation of cAMP stimulates lipolysis and the release of various hormones, such as dopamine, epinephrine, and norepinephrine [16].

2.4. Adverse Effects and Toxicity of Caffeine

Moderate caffeine consumption, i.e. up to 400 mg per day, is generally considered to be safe for adults [10,29,36]. Moreover, a single dose of caffeine up to 200 mg poses no safety concerns for healthy adults [36]. Nonetheless, high single doses of caffeine above 300 mg may result in acute caffeine intoxication [10]. The most frequent symptoms are nervousness, restlessness, irritability, anxiety or insomnia [37], as well as manifestations related to the cardiovascular, gastrointestinal and urinary systems [10]. A chronic intake of caffeine higher than 400-600 mg/day has been associated with diverse dysfunctions [29].
The majority of negative side effects are related to the stimulatory effects of caffeine [29]. Increased caffeine consumption can induce anxiety and affect mood [38]. Intake of 100 mg or more of caffeine may prolong sleep onset and decrease sleep duration, particularly when consumed close to bedtime [29,36].
Furthermore, caffeine appears to have addictive properties. Sudden discontinuation of regular caffeine intake can lead to caffeine withdrawal syndrome, as described in the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association (APA) [39]. Symptoms include headache, drowsiness, lethargy, fatigue, reduced motivation, self-confidence, and increased irritability, as well as a decrease in blood pressure [29,40]. Caffeine withdrawal symptoms occur 12-24 hours after the last consumption of caffeine and reach their peak after 20-48 hours [29]. To prevent caffeine withdrawal syndrome, gradual reduction of ingested caffeine doses is recommended.
For many years, caffeine consumption has been believed to be associated with negative health outcomes, particularly related to cardiovascular events. Recently however, this opinion has been subjected to a significant re-evaluation. The impact of caffeine on the cardiovascular system is therefore reviewed in the following paragraphs.

3. Adenosine Receptor Characteristics

3.1. Overview

Adenosine plays an important role in the human body. It exerts its effects through the activation of four different adenosine receptors (ARs): A1, A2A, A2B and A3 [41,42]. Each AR has the same core domain but is characterised by a different number of amino acids [43]. Adenosine receptors are G protein-coupled receptors (purinergic receptors, P1R), classified as either adenylyl cyclase inhibitors (A1 and A3) or adenylyl cyclase activators (A2A and A2B) [44]. While stimulation of A2A and A2B increases cAMP production, followed by the activation of protein kinase A (PKA) and phosphorylation of CREB protein (cAMP response element binding protein), stimulation of A1 and A3AR has the opposite effect [45].
Although GPCRs (G protein-coupled receptors) were previously viewed as monomeric units interacting one-to-one with their respective heterotrimeric G proteins, this view has changed [46]. It has been shown that GPCRs (including adenosine receptors) can occur in homomeric, oligomeric and heteromeric forms, and heteromers are characterised by novel functional (signalling) properties compared to homomers [47,48]. A2AR heteromers can be found in several combinations, including A1R-A2AR, A2AR-A2BR, A2AR-D2R, A2AR-D3R and A2AR-D4R4; however, the A2AR-D2R heteroreceptor complex is of the greatest interest as it plays a role in Parkinson's disease, schizophrenia and cocaine addiction [47].

3.2. Function of Adenosine Receptors

Adenosine receptors are widely expressed and have been implicated in several physiological and pathological biological functions. They are found in among others, the neurological, cardiovascular, respiratory, gastrointestinal, urogenital and immunological systems [43,49]. In addition, AR can also be found in the bones, joints, eyes and skin [43,49]. Each AR has a distinct cell and tissue distribution and secondary signalling transducers [43]. The A1AR and A3AR signals are mediated by Gi and Go proteins, while the other two are linked to Go proteins [41]. However, all AR subtypes are present in the heart [50].
A1AR is present in the atrium, smooth muscles and endothelial coronary tissues [51,52]. It can be also found in the central nervous system (CNS) with high levels in the cerebral cortex, hippocampus, cerebellum, thalamus, brainstem and spinal cord [53]. It regulates functions such as neurotransmitter release, reduction of neuronal excitability or pain relief [43,54]. However, it is also responsible for some negative effects in other tissues and systems: it reduces renal blood flow and suppresses insulin secretion and lipolysis [43,45] and is responsible for pro-inflammatory effects in several immune cells [42,43].
The A3AR subtype can be found in a variety of primary cells, tissues and cell lines [43,53]. It is expressed in smooth muscle cells such as coronary artery muscle cells [55,56]. It is also able to mediate anti-inflammatory effects in inflammatory cells such as eosinophils, neutrophils, monocytes and macrophages [43]. The A3AR subtype has also been implicated in allergic responses and apoptosis [53].
The A2AAR subtype is widely expressed centrally and peripherally, but mostly in the striatum, olfactory tubercle and immune system [43]. This subtype can be found in leukocytes, platelets and blood vessels, where its role is to mediate a variety of anti-inflammatory, antiaggregatory and vasodilatory effects [53,54]. In the cardiovascular system, A2AAR is expressed in the vessels, atria and ventricular tissues [51,57]. It also plays an important role in Parkinson's disease, Huntington's disease, Alzheimer's disease and ischaemia [53]. Interestingly, both the A3AR and A2AAR subtypes are associated with cancer, but they have different effects [43]. In addition, activation of the A2AAR pathway suppresses the synthesis and release of inflammatory cytokines [58].
Finally, the A2BAR subtype can be found in various cell types in the intestine, bladder, vas deferens and lung [53]. It has also been observed on myocytes, fibroblasts and in the smooth muscles of coronary arteries [59,60]. Like the other subtypes, A2BAR may also play a role in modulating inflammation and immune processes [61]. This subtype appears to be upregulated in hypoxia, inflammation and cell stress [43].
Table 1. Role of adenosine receptor (AR) subtypes in cardiovascular system.
Table 1. Role of adenosine receptor (AR) subtypes in cardiovascular system.
Subtype of adenosine receptos Role in cardiovascular system Citation
A1 Vessel tone regulation
Heart rate reduction
New vessels formation
Cardioprotecion		 [62]
[50]
[50]
[63]
A2A Vasodilation
Wound healing
Angiogenesis
Vasculogenesis
Blood pressure regulation
Blood flow regulation
Cardioprotection
Inhibition of platelet function		 [50]
[50]
[64]
[64]
[65]
[66]
[63]
[67]
A2B Vasodilation
Blood pressure regulation
Blood flow regulation
Angiogenesis
Vasculogenesis		 [50]
[65]
[66]
[64]
[64]
A3 Cardioprotection
Blood pressure regulation		 [63]
[65]

4. The Role of Platelets in Cardiovascular System Function

Among the various roles of platelets, one of their most important is their involvement in haemostasis and thrombosis. In pathological conditions, platelets are activated to prevent excessive blood loss. During primary haemostasis, activated cells adhere to the vessel endothelium and form aggregates. Additionally, platelets play a significant part in thrombosis. Upon their activation, platelets release several substances including fibrinogen, which is then converted into fibrin; this supports their role in thrombosis and in wound healing [68]. Platelets also release various substances to support wound healing, such as growth factors, cytokines and chemokines [69] and enhance thrombin production [69]. However, while their involvement in both haemostasis and thrombosis is widely acknowledged, their other roles should not be disregarded.
Platelets play a crucial role in maintaining vascular integrity and proper blood flow within vessels [70,71]. Studies have shown that platelets support the vascular endothelium through four mechanisms: filling potential gaps, stimulating endothelial cell growth, assisting in the maintenance of endothelium ultrastructure, and finally releasing factors that improve endothelial barrier function [71]. They also exhibit proangiogenic properties through the use of the pro- and anti-angiogenic factors within their granules [71]. Platelets also participate in inflammatory processes and thus possess a significant role in inflammation [68].
However, while platelets appears to contribute to the development of cardiovascular disease, they may also provide cardioprotective benefits. They have also been shown to support heart muscle regeneration after a myocardial infarction (MI) [72]. Furthermore, their protective properties are evident in their ability to preserve vascular integrity in the face of inflammation [71].

5. Adenosine Receptors-Mediated Effects of Caffeine on Platelets

Human blood platelets express receptors A2AAR and A2BAR [73,74]. Platelets have a significantly greater density of A2AARs, than A2BARs, and previous studies suggest was the sole receptor involved in adenosine- stimulated platelet activation [75]. Early studies identified A2AAR to be an important receptor expressed on platelets and to mediate adenosine inhibition of platelet aggregation. Caffeine is proposed to act as a weak A2AR antagonist; however, some functional studies based on cells and experimental Parkinsons suggest that it may behave as an inverse agonist [76].
Significantly fewer studies have investigated the effects of coffee on platelet function compared to those examining the effect on serum lipids and blood pressure [77,78,79,80,81,82,83,84,85,86]. Generally, it seems reasonable to conclude that coffee extracts are effective in inhibiting platelet aggregation, a critical step of primary haemostasis and thrombosis. It has been shown that coffee possesses antiplatelet activity, and inhibits platelet aggregation induced by adenosine diphosphate, collagen, arachidonic acid, and epinephrine [78,79,83,85,86]. In another study, coffee extracts were found to have anti-aggregatory effects on in vitro platelet aggregation induced by ADP or arachidonate, but not by collagen [80]. Some authors suggested that the antiplatelet effect of coffee is probably independent from caffeine and could be a result of the interaction of coffee phenolic acids with the intracellular signalling network, which is known to lead to platelet aggregation [86].
Nevertheless, it has also been observed that caffeine might stimulate platelet reactivity in vivo; administration of 100 mg of caffeine has been found to increase the release of β thromboglobulin one hour later [77]. Cavalcante et al. report no changes in ADP-, collagen- and adrenaline-stimulated platelet aggregation in individuals receiving 750 mg/day of caffeine; although diastolic pressure significantly increased 24 hours after the first intake, this effect, disappeared in the following seven days [82].
In other in vitro studies, samples treated with caffeine (770 µM or 1540 µM) demonstrated significantly lower mean platelet aggregation following epinephrine or ADP treatment compared to control samples. No significant differences were observed in mean values of collagen- or ristocetin-induced platelet aggregability. These results suggest that caffeine selectively inhibits epinephrine- and ADP-stimulated platelet aggregation and disturbs the release of endogenous ADP from platelets in response to exogenous ADP [87].
It was also observed that chronic caffeine intake could affect ADP-induced platelet aggregation, but only when the intake lasted longer than one week and was higher than 400 mg/d [86]. Coffee consumption was found to significantly reduce collagen- and arachidonic acid-stimulated blood platelet aggregation at both the 30 and 60-min time points; however, coffee had no significant influence in blood platelet aggregation stimulated by ADP [86]. Hence, coffee consumption was found to have anti-platelet effects.
It has been proposed that caffeine exerts its anti-platelet activity via cAMP (3′,5′-cyclic adenosine monophosphate), an important second messenger in blood platelets. It was found that caffeine increased the level of cAMP, most likely by inhibition of phosphodiesterase. In vivo studies indicate that coffee consumption significantly inhibited phosphodiesterase activity, and selected coffee constituents such as caffeine, theophylline, paraxanthine and caffeine metabolites (0.1–5 mM), inhibited PDE activity in blood platelets in vitro. The authors suggest that moderate consumption of coffee may modulate blood platelet aggregation, at least in part by altering PDE activity and cAMP homeostasis [88].
Baggioni et al. found that chronic intake of coffee alters the response of platelets to the activity of adenosine- or NECA-induced (NECA - non-selective agonist of adenosine receptor) platelet inhibition [89]; the authors propose that chronic exposure to caffeine may sensitize or upregulate the adenosine receptors. Similarly, [90] observed that seven-day administration of 750 mg caffeine per day (3 x 250 mg) resulted in changes in ADP-induced platelet aggregation, increased cAMP accumulation and A2A adenosine receptor upregulation 12 or 60 hours after the last dose of caffeine [90]. In addition, Varani et al. report that intake of caffeine (400 or 600 mg/day for one week or 400 mg/d for two weeks) may upregulate A2A adenosine receptor activity, increase cAMP accumulation and anti-aggregatory effects, and decrease calcium levels elicited by HE-NECA in a time-dependent and dose dependent manner [91].
Although such changes can influence platelet function, caffeine tolerance probably does not alter the potency of caffeine as a competitive antagonist to adenosine. It is more likely that caffeine tolerance may be increased by other changes, such as a shift in receptor to a high-affinity state, alterations in G protein levels or the coupling of these proteins to adenosine receptors or long-term receptor occupancy. It is nevertheless possible that while chronic caffeine intake may enhance the antiplatelet activity of adenosine and its analogues, acute intake may lower the activity due to antagonism of A2A receptors.

5.1. Can Caffeine Modulate Effects of Inhibitors of Adenosine Receptors on Platelets?

Activation of blood platelets plays a crucial role in the initiation and development of arterial thrombotic diseases, such as coronary heart disease and stroke. Therefore, the ‘first choice’ in the management and treatment of arterial thrombotic disorders is antiplatelet therapy. Despite the fact that many anti-platelet agents are currently available, and some of them are approved and widely applied, an effective treatment of arterial thrombosis remains elusive. This problem is twofold: either antiplatelet agents (e.g. aspirin) interfere with only one of the several pathways of platelet activation, or they may (e.g. fibrinogen receptor blockers) very effectively block the final common step but pose a risk of bleeding. Also, the activity of many antiplatelet agents varies considerably in response to environmental or genetic factors. As such, still there is a need for novel platelet inhibitors with better efficacy and safety, or treatments based on a combined therapy of currently-available agents.
One promising strategy for effective anti-platelet therapy is based on targeting multiple platelet activation pathways. Recently, it was proposed that the inhibition of platelet function by P2Y12 antagonists can be potentiated by adenosine receptor agonists [67]. In addition, exposure to certain adenosine receptor agonists: UK432097, 2-chloroadenosine, MRE0094 and PSB0777, preserved platelet viability with no cytotoxic effects being observed [92]. A group of AR agonists was found to have significant anti-platelet activity, as indicated by multiple parameters of platelet function: aggregation in whole blood and platelet-rich plasma [92], P-selectin expression, GPIIb-IIIa activation, fibrinogen binding, and calcium ion mobilization [93]. The results confirm that AR agonists demonstrate a synergistic effect with P2Y12 antagonists, resulting in greater inhibition of ADP-induced platelet activation; in addition, it was found that the AR agonists, both alone and in combination with a P2Y12 antagonist, increase cAMP formation in both unstimulated and ADP-activated platelets, suggesting that the mechanism is cAMP dependent [93].
Interestingly, the antiplatelet effects of AR agonist was found to be heterogeneous in a combined model comprising blood samples incubated with AR agonist and cangrelor or prasugrel metabolite (PM). When whole group of healthy subjects was divided into two subpopulations: high responders and low-responders to P2Y12 receptor inhibitors, separately for cangrelor and PM, statistical significant difference was found between both responder groups for each agonist-antagonist pairing [94]. The P2Y12 antagonist low-responders demonstrated markedly higher inhibition of AR-stimulated platelet response than high-responders, as indicated by the aggregation increase factor, i.e. the number of times an anti-aggregatory effect is intensified by an AR agonist. Interestingly, combinations of stronger AR agonists (NECA, and to a smaller extent regadenoson) with a P2Y12 antagonist achieved comparable inhibition of overall aggregation in both the high- and low-responder groups [94]. This suggests that patients with resistance to P2Y12 inhibitors could potentially particularly benefit from adenosine receptor-targeted therapy.
The effect of AR agonists and P2Y12 inhibitors on thrombus formation was also assayed with the use of the Venaflux system using Vena8 Fluoro+ biochips coated with type I collagen. Blood samples incubated with AR agonists (NECA 0.5 µM, regadenoson 1.2 µM) and/or P2Y12 inhibitor cangrelor (17 nM) were perfused through the channels of a chip using a shear force of 60 dyn/cm2. Under applied conditions, the AR agonists (NECA and regadenoson) alone decreased clot formation by a mean value of 84%. Cangrelor alone decreased clot formation by 68.3%. Interestingly, pairing the AR agonists with a P2Y12 inhibitor improved the antiplatelet effect. In general, the observed inhibitory effect on thrombus formation was stronger than could be expected taking into account the results obtained in aggregation experiments [93].
Finally, these effects were confirmed using an in vivo model of ferric chloride-induced thrombosis in mice. In this model, HE-NECA was found to potentiate the anti-thrombotic effects of either cangrelor or prasugrel. HE-NECA demonstrated efficacy both when administered chronically and in bolus form, as noted previously for other AR agonists [95]. It is known that AR agonists can elevate blood-brain barrier permeability and have a hypotensive impact. Indeed, it was found that bolus HE-NECA administration significantly reduced blood pressure, although this impact was much less pronounced when the drug was administered in dosages equivalent to those achieved from chronic administration. In addition, HE-NECA was not observed to have any significant effect on the blood–brain barrier [95].
Generally, these findings support the idea of dual anti-platelet therapy; they confirm the potential value of platelet adenosine receptors as therapeutic targets and the benefits of therapeutic use of combined P2Y12 antagonist and AR agonist therapy in cardioprotection.
In the light of above findings, it would be interesting to verify a role of caffeine and its metabolites in a reduction of platelet reactivity by selective adenosine agonists of A2A receptor. Not only caffeine, but also their main metabolites may modulate cell function via adenosine receptors and inhibition of cyclic nucleotide phosphodiesterases. Interestingly, a chronic abuse of caffeine in humans (drinking coffee) leads to the overexpression of A2aR in platelets accompanied by platelet sensitization and stronger reaction to adenosine analogue HE-NECA and reduction of platelet activation. In the context of antiplatelet activity of caffeine per se or in combination with adenosine analogues, the mechanism related to the increasing in intraplatelet cAMP concentration via PDE inhibition is the most probable, but it is also possible that the analogues with the stronger affinity for the A2a receptor could be less influenced by caffeine than adenosine. Additionally, the effects of the direct interaction of caffeine and its metabolites with A2a receptors in the context of the adenosine analogues influence on platelets are less known. It is also interesting to investigate whether antiplatelet activity of A2AR agonists differs between low and fast caffeine metabolisers or is modulated by nucleotide polymorphisms in A2AR. Therefore, it cannot be excluded that the metabolism of caffeine largely determines a variability of the antiplatelet activity of the selected adenosine A2A receptor agonists. Currently however, according to our knowledge, there are no direct experimental evidence supporting the above hypothesis.

6. Adenosine Receptor-Mediated Effects of Caffeine on the Cardiovascular System

Adenosine plays an important role as a regulator and modulator of the cardiovascular system [96]. It exerts its cardiovascular effects mainly through A1 adenosine receptors [66], a subtype involved in the regulation of blood pressure [97]. Caffeine blocks adenosine receptors, and complete blockade increases systemic levels of adenosine [98]; thus circulating chemoreceptors and other receptors are stimulated, increasing sympathetic tone, catecholamine level, peripheral vascular resistance and renin secretion [98]. Stimulation of the A1R leads to a contraction of vascular smooth muscle and to a decrease in coronary blood flow [99]. In addition, caffeine alters total peripheral resistance, diuresis and heart rate [65].
Caffeine can have a dual effect on blood pressure by antagonising the adenosine receptors A1R, A2AR and A2BR [65]. While caffeine was historically believed to increase blood pressure, recent studies suggest a different relationship between adenosine and caffeine. Although blood pressure indeed increases shortly after caffeine consumption, it does not seem to have long-term effects [100]. Studies indicate that while caffeine has an acute effect on both systolic and diastolic blood pressure, long-term consumption does not appear to have a chronic effect [65,98,101]. Interestingly, habitual coffee drinking may in fact reduce the risk of cardiovascular disease and hypertension [100]. Caffeine has been shown not only to affect blood pressure, but also to increase systemic vascular resistance [102].
The pressor effect of caffeine acts mainly by altering vessel resistance [103]. Caffeine is also able to improve endothelial cell function by increasing cellular calcium, thus stimulating nitric oxide (NO) production [98]. NO stimulates vasodilation by acting on vascular smooth muscle [98,104]. Studies suggest that caffeine affects arterial stiffness in both normal and hypertensive subjects, but that this effect lasts longer in the second group [105,106]; this hypothesis has been supported by other studies [107,108]. In addition, chronic coffee consumption also has a negative effect on wave reflections in healthy subjects [107].
However, regular coffee consumption has positive effects. The habit of drinking coffee may be associated with a lower risk of developing hypertension, heart failure and atrial fibrillation [109]. Studies suggest the existence of a J-shaped relationship between caffeine consumption and the risk of developing coronary heart disease [109]: i.e. moderate caffeine consumption is associated with a reduced risk of CVD, and may even be protective against CVD, whereas heavy coffee consumption is associated with an increased risk of CVD [109,110].

7. Concluding Remarks

Caffeine is known to affect various aspects of physiology, including the cardiovascular system. Although for many years it was thought to have a negative effect on blood pressure, cardiovascular events and morbidity, recent evidence suggests the opposite. Caffeine consumption appears to have a range of health benefits, including a protective effect against CVD. Adenosine receptors play an important role in mediating the effects of caffeine on the cardiovascular system and blood platelets. While all subtype of adenosine receptors (ARs) are involved in this process, the effects on the cardiovascular system are mainly exerted through A1AR. Stimulation of A1AR results in the contraction of vascular smooth muscle and decrease in coronary blood flow. Caffeine intake seems to have dual effect on blood pressure. It increases systemic vascular resistance and arterial stiffness. It is also able to improve endothelial cell function, but have a negative effect on wave reflection.
Overall, consumption of coffee, the richest source of dietary caffeine, seems to be beneficial. Moderate caffeine intake may be associated with a lower risk of CVD. Consumption also has anti-thrombotic and anti-platelet effects, and appears to inhibit platelet aggregation. Knowledge of the relationship between coffee consumption and platelet aggregation may be of great value for both nutritionists and clinicians: not only caffeine may affect human health, but also because it may be able to modulate the effects of some drugs, especially those used in antiplatelet therapy.

Author Contributions

KM – writing a first draft of the manuscript, literature search, preparing figures and tables; BL – concept of the paper, critical review of the manuscript; MR – concept of the paper, editing and revision of the manuscript, writing the final version of the manuscript.

Funding

This research was funded by Medical University of Lodz, Poland (503/6-020-01/503-61-001-19-00).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Biaggioni, I.; Paul, S.; Puckett, A.; Arzubiaga, C. Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 1991, 258, 588–593. [Google Scholar] [PubMed]
  2. Chen, Y.; Zhang, Y.; Zhang, M.; Yang, H.; Wang, Y. Consumption of coffee and tea with all-cause and cause-specific mortality: a prospective cohort study. BMC Med 2022, 20, 449. [Google Scholar] [CrossRef] [PubMed]
  3. Dong, X.; Li, S.; Sun, J.; Li, Y.; Zhang, D. Association of Coffee, Decaffeinated Coffee and Caffeine Intake from Coffee with Cognitive Performance in Older Adults: National Health and Nutrition Examination Survey (NHANES) 2011-2014. Nutrients 2020, 12, 840. [Google Scholar] [CrossRef] [PubMed]
  4. Kondo, Y.; Goto, A.; Noma, H.; Iso, H.; Hayashi, K.; Noda, M. Effects of Coffee and Tea Consumption on Glucose Metabolism: A Systematic Review and Network Meta-Analysis. Nutrients 2018, 11, 48. [Google Scholar] [CrossRef] [PubMed]
  5. Coffee Report and Outlook, 2023, International Coffee Organization. Available online: https://icocoffee.org/documents/cy2023-24/Coffee_Report_and_Outlook_December_2023_ICO.pdf (accessed on 19 June 2024).
  6. National Coffee Data Trends 2022. n.d., National Coffee Association. Available online: https://www.ncausa.org/Newsroom/Coffee-consumption-hits-two-decade-high-2022-NCDT (accessed on 19 June 2024).
  7. Thiriet, M. Cardiovascular Disease: An Introduction. Vasculopathies. 2018, 1–90. [Google Scholar]
  8. World Heart Report 2023: Confronting the World’s Number One Killer; World Heart Federation: Geneva, Switzerland, 2023; Available online: https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf (accessed on 19 June 2024).
  9. Coronado, F.; Melvin, S.C.; Bell, R.A.; Zhao, G. Global Responses to Prevent, Manage, and Control Cardiovascular Diseases. Prev Chronic Dis 2022, 19, E84. [Google Scholar] [CrossRef] [PubMed]
  10. Rodak, K.; Kokot, I.; Kratz, E.M. Caffeine as a Factor Influencing the Functioning of the Human Body-Friend or Foe? Nutrients 2021, 13, 3088. [Google Scholar] [CrossRef] [PubMed]
  11. Weng, Z.; Xu, C.; Xu, J.; Jiang, Z.; Liu, Q.; Liang, J.; Gu, A. Association of urinary caffeine and caffeine metabolites with cardiovascular disease risk in adults. Nutrition 2021, 84, 111121. [Google Scholar] [CrossRef] [PubMed]
  12. Ding, Q.; Xu, Y.M.; Lau, A.T.Y. The Epigenetic Effects of Coffee. Molecules 2023, 28, 1770. [Google Scholar] [CrossRef]
  13. Socała, K.; Szopa, A.; Serefko, A.; Poleszak, E. ; Wlaź; P Neuroprotective Effects of Coffee Bioactive Compounds: A Review. Int J Mol Sci 2020, 22, 107. [Google Scholar] [CrossRef]
  14. Ribeiro, J.A.; Sebastiao, A.M. Caffeine and Adenosine. J Alzheimers Dis. 2010, Suppl 1, S3–15. [Google Scholar] [CrossRef]
  15. Evans, J.; Richards, J.R.; Battisti, A.S. Caffeine in StatPearls. 2023, Treasure Island (FL): StatPearls Publishing. Available online: https://www.ncbi.nlm.nih.gov/books/NBK519490/ (accessed on 19 June 2024).
  16. Cappelletti, S.; Piacentino, D.; Sani, G.; Aromatario, M. Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug? Curr Neuropharmacol 2015, 13, 71–88. [Google Scholar] [CrossRef] [PubMed]
  17. Ashihara, H.; Crozier, A. Caffeine: a well known but little mentioned compound in plant science. Trends Plant Sci 2001, 6, 407–413. [Google Scholar] [CrossRef]
  18. Pharmacology of Caffeine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations; National Academies Press (US): Washington, DC, USA, 2001; Available online: https://www.ncbi.nlm.nih.gov/books/NBK223808/ (accessed on 19 June 2024).
  19. Stefanello, N.; Spanevello, R.M.; Passamonti, S.; Porciúncula, L.; Bonan, C.D.; Olabiyi, A.A.; Teixeira da Rocha, J.B.; Assmann, C.E.; Morsch, V.M.; Schetinger, M.R.C. Coffee, caffeine, chlorogenic acid, and the purinergic system. Food Chem Toxicol 2019, 123, 298–313. [Google Scholar] [CrossRef] [PubMed]
  20. Nehlig, A. Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption. Pharmacol Rev 2018, 70, 384–411. [Google Scholar] [CrossRef] [PubMed]
  21. Temple, J.L.; Bernard, C.; Lipshultz, S.E.; Czachor, J.D.; Westphal, J.A.; Mestre, M.A. The Safety of Ingested Caffeine: A Comprehensive Review. Front Psychiatry 2017, 8, 80. [Google Scholar] [CrossRef] [PubMed]
  22. Grzegorzewski, J.; Bartsch, F.; Köller, A.; König, M. Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing. Front Pharmacol 2021, 12, 752826. [Google Scholar] [CrossRef]
  23. Cornelis, M.C.; Kacprowski, T.; Menni, C.; Gustafsson, S.; Pivin, E.; Adamski, J.; Artati, A.; Eap, C.B.; Ehret, G.; Friedrich, N.; et al. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. Hum Mol Genet 2016, 25, 5472–5482. [Google Scholar] [CrossRef] [PubMed]
  24. Urry, E.; Jetter, A.; Landolt, H.P. Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake. Nutr Metab (Lond) 2016, 13, 66. [Google Scholar] [CrossRef]
  25. Bjørngaard, J.H.; Nordestgaard, A.T.; Taylor, A.E.; Treur, J.L.; Gabrielsen, M.E.; Munafò, M.R.; Nordestgaard, B.G.; Åsvold, B.O.; Romundstad, P.; Davey Smith, G. Heavier smoking increases coffee consumption: findings from a Mendelian randomization analysis. Int J Epidemiol 2017, 46, 1958–1967. [Google Scholar] [CrossRef]
  26. Djordjevic, N.; Ghotbi, R.; Bertilsson, L.; Jankovic, S.; Aklillu, E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C>A polymorphism. Eur J Clin Pharmacol 2010, 66, 697–703. [Google Scholar] [CrossRef] [PubMed]
  27. Carswell, A.T.; Howland, K.; Martinez-Gonzalez, B.; Baron, P.; Davison, G. The effect of caffeine on cognitive performance is influenced by CYP1A2 but not ADORA2A genotype, yet neither genotype affects exercise performance in healthy adults. Eur J Appl Physiol 2020, 120, 1495–1508. [Google Scholar] [CrossRef] [PubMed]
  28. Pickering, C.; Kiely, J. Are the Current Guidelines on Caffeine Use in Sport Optimal for Everyone? Inter-individual Variation in Caffeine Ergogenicity, and a Move Towards Personalised Sports Nutrition. Sports Med 2018, 48, 7–16. [Google Scholar] [CrossRef]
  29. dePaula, J.; Farah, A. Caffeine Consumption through Coffee: Content in the Beverage, Metabolism, Health Benefits and Risks. Beverages 2019, 5, 37. [Google Scholar] [CrossRef]
  30. Graham, T.E.; Sathasivam, P.; Rowland, M.; Marko, N.; Greer, F.; Battram, D. Caffeine ingestion elevates plasma insulin response in humans during an oral glucose tolerance test. Can J Physiol Pharmacol 2001, 79, 559–565. [Google Scholar] [CrossRef]
  31. Salomone, F.; Galvano, F.; Li Volti, G. Molecular Bases Underlying the Hepatoprotective Effects of Coffee. Nutrients 2017, 9, 85. [Google Scholar] [CrossRef]
  32. Barcelos, R.P.; Lima, F.D.; Carvalho, N.R.; Bresciani, G.; Royes, L.F. Caffeine effects on systemic metabolism, oxidative-inflammatory pathways, and exercise performance. Nutr Res 2020, 80, 1–17. [Google Scholar] [CrossRef]
  33. Shushtari, N.; Abtahi Froushani, S.M. Caffeine Augments The Instruction of Anti-Inflammatory Macrophages by The Conditioned Medium of Mesenchymal Stem Cells. Cell J 2017, 19, 415–424. [Google Scholar]
  34. Kong, H.; Jones, P.P.; Koop, A.; Zhang, L.; Duff, H.J.; Chen, S.R. Caffeine induces Ca2+ release by reducing the threshold for luminal Ca2+ activation of the ryanodine receptor. Biochem J 2008, 414, 441–452. [Google Scholar] [CrossRef]
  35. Rosser, J.I.; Walsh, B.; Hogan, M.C. Effect of physiological levels of caffeine on Ca2+ handling and fatigue development in Xenopus isolated single myofibers. Am J Physiol Regul Integr Comp Physiol 2009, 296, R1512–R1517. [Google Scholar]
  36. Scientific Opinion on the safety of caffeine. EFSA Journal 2015, 13. Available online: https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.4102 (accessed on 19 June 2024).
  37. Pina Cabral, J.; Sousa, D.L.; Carvalho, C.; Girao, A.; Pacheco Mendes, A.; Pina, R. Caffeine Intoxication: Unregulated, Over-the-Counter Sale of Potentially Deadly Supplements. Cureus 2022, 14, e21045. [Google Scholar] [CrossRef] [PubMed]
  38. Nawrot, P.; Jordan, S.; Eastwood, J.; Rotstein, J.; Hugenholtz, A.; Feeley, M. Effects of caffeine on human health. Food Addit Contam 2003, 20, 1–30. [Google Scholar] [CrossRef] [PubMed]
  39. Budney, A.J.; Brown, P.C.; Griffiths, R.R.; Hughes, J.R.; Juliano, L.M. Caffeine Withdrawal and Dependence: A Convenience Survey Among Addiction Professionals. J Caffeine Res 2013, 3, 67–71. [Google Scholar] [CrossRef] [PubMed]
  40. Meredit, S.E.; Juliano, L.M.; Hughes, J.R.; Griffiths, R.R. Caffeine Use Disorder: A Comprehensive Review and Research Agenda. J Caffeine Res 2013, 3, 114–130. [Google Scholar] [CrossRef] [PubMed]
  41. Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacol Rev. 2001, 53, 527–552. [Google Scholar] [PubMed]
  42. Vincenzi, F.; Pasquini, S.; Contri, C.; Cappello, M.; Nigro, M.; Travagli, A.; Merighi, S.; Gessi, S.; Borea, P.A.; Varani, K. Pharmacology of Adenosine Receptors: Recent Advancements. Biomolecules 2023, 13, 1387. [Google Scholar] [CrossRef] [PubMed]
  43. Borea, P.A.; Gessi, S.; Merighi, S.; Vincenzi, F.; Varani, K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev 2018, 98, 1591–1625. [Google Scholar] [CrossRef] [PubMed]
  44. Koupenova, M.; Ravid, K. Biology of Platelet Purinergic Receptors and Implications for Platelet Heterogeneity. Front Pharmacol 2018, 9, 37. [Google Scholar] [CrossRef]
  45. Sheth, S.; Brito, R.; Mukherjea, D.; Rybak, L.P.; Ramkumar, V. Adenosine receptors: expression, function and regulation. Int J Mol Sci 2014, 15, 2024–2052. [Google Scholar] [CrossRef]
  46. Vecchio, E.A.; Baltos, J.A.; Nguyen, A.T.N.; Christopoulos, A.; White, P.J.; May, L.T. New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. Br J Pharmacol 2018, 175, 4036–4046. [Google Scholar] [CrossRef]
  47. Borroto-Escuela, D.O.; Fuxe, K. Oligomeric Receptor Complexes and Their Allosteric Receptor-Receptor Interactions in the Plasma Membrane Represent a New Biological Principle for Integration of Signals in the CNS. Front Mol Neurosci 2019, 12, 230. [Google Scholar] [CrossRef] [PubMed]
  48. Ferré, S.; Sarasola, L.I.; Quiroz, C.; Ciruela, F. Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum. Neuropharmacology 2023, 223, 109329. [Google Scholar] [CrossRef] [PubMed]
  49. Peleli, M.; Fredholm, B.B.; Sobrevia, L.; Carlström, M. Pharmacological targeting of adenosine receptor signaling. Mol Aspects Med 2017, 55, 4–8. [Google Scholar] [CrossRef] [PubMed]
  50. Guieu, R.; Deharo, J.C.; Maille, B.; Crotti, L.; Torresani, E.; Brignole, M.; Parati, G. Adenosine and the Cardiovascular System: The Good and the Bad. J Clin Med 2020, 9, 1366. [Google Scholar] [CrossRef] [PubMed]
  51. Headrick, J.P.; Ashton, K.J.; Rose'meyer, R.B.; Peart, J.N. Cardiovascular adenosine receptors: Expression, actions and interactions. Pharmacology & Therapeutics 2013, 140, 92–111. [Google Scholar]
  52. Hussain, T.; Mustafa, S.J. Binding of Ax Adenosine Receptor Ligand [3H] 8-Cyclopentyl-l,3-Dipropylxanthine in Coronary Smooth Muscle. Circulation Research 1995, 77, 194–198. [Google Scholar] [CrossRef] [PubMed]
  53. Klaasse, E.C.; Ijzerman, A.P.; de Grip, W.J.; Beukers, M.W. Internalization and desensitization of adenosine receptors. Purinergic Signal 2008, 4, 21–37. [Google Scholar] [CrossRef] [PubMed]
  54. Effendi, W.I.; Nagano, T.; Kobayashi, K.; Nishimura, Y. Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases. Cells 2020, 9, 785. [Google Scholar] [CrossRef]
  55. Zhao, Z.; Makaritsis, K.; Francis, C.E.; Gavras, H.; Ravid, K. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim Biophys Acta 2000, 1500, 280–290. [Google Scholar] [CrossRef]
  56. Belardinelli, L.; Shryock, J.C.; Song, Y.; Wang, D.; Srinivas, M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. The FASEB Journal 1995, 9, 359–365. [Google Scholar] [CrossRef] [PubMed]
  57. Iwamoto, T.; Umemura, S.; Toya, Y.; Uchibori, T.; Kogi, K.; Takagi, N.; Ishii, M. Identification of Adenosine A2 Receptor-cAMP System in Human Aortic Endothelial Cells. Biochem Biophys Res Commun 1994, 199, 905–910. [Google Scholar] [CrossRef] [PubMed]
  58. Ye, H.; Zhao, J.; Xu, X.; Zhang, D.; Shen, H.; Wang, S. Role of adenosine A2a receptor in cancers and autoimmune diseases. Immun Inflamm Dis 2023, 11, e826. [Google Scholar] [CrossRef] [PubMed]
  59. Dobson, J.G., Jr.; Fenton, R.A. Adenosine A receptor function in rat ventricular myocytes. Cardiovasc Res 1996, 34, 337–347. [Google Scholar] [CrossRef] [PubMed]
  60. Morrison, R.R.; Talukder, M.A.; Ledent, C.; Mustafa, S.J. Cardiac effects of adenosine in A2A receptor knockout hearts: uncovering A2B receptors. Am J Physiol Heart Circ Physiol 2002, 282, H437–H444. [Google Scholar] [CrossRef] [PubMed]
  61. Eisenstein, A.; Patterson, S.; Ravid, K. The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases. J Cell Physiol 2015, 230, 2891–2897. [Google Scholar] [CrossRef] [PubMed]
  62. Tawfik, H.E.; Schnermann, J.; Oldenburg, P.J.; Mustafa, S.J. Role of A1 adenosine receptors in regulation of vascular tone. Am J Physiol Heart Circ Physiol 2005, 288, H1411–H1416. [Google Scholar] [CrossRef] [PubMed]
  63. McIntosh, V.J.; Lasley, R.D. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther 2012, 17, 21–33. [Google Scholar] [CrossRef]
  64. Feoktistov, I.; Biaggioni, I.; Cronstein, B.N. Adenosine receptors in wound healing, fibrosis and angiogenesis. Handb Exp Pharmacol 2009, 193, 383–397. [Google Scholar]
  65. Surma, S.; Oparil, S. Coffee and Arterial Hypertension. Curr Hypertens Rep 2021, 23, 38. [Google Scholar] [CrossRef]
  66. Mustafa, S.J.; Morrison, R.R.; Teng, B.; Pelleg, A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol 2009, 161–188. [Google Scholar]
  67. Wolska, N.; Rozalski, M. Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy. Int J Mol Sci 2019, 20, 5475. [Google Scholar] [CrossRef] [PubMed]
  68. Repsold, L.; Joubert, A.M. Platelet Function, Role in Thrombosis, Inflammation, and Consequences in Chronic Myeloproliferative Disorders. Cells 2021, 10, 3034. [Google Scholar] [CrossRef] [PubMed]
  69. Smyth, S.S.; McEver, R.P.; Weyrich, A.S.; Morrell, C.N.; Hoffman, M.R.; Arepally, G.M.; French, P.A.; Dauerman, H.L.; Becker, R.C. 2009 Platelet Colloquium Participants.Platelet functions beyond hemostasis. J Thromb Haemost 2009, 7, 1759–1766. [Google Scholar] [CrossRef] [PubMed]
  70. Holinstat, M. Normal platelet function. Cancer Metastasis Rev 2017, 36, 195–198. [Google Scholar] [CrossRef]
  71. Ho-Tin-Noe, B.; Demers, M.; Wagner, D.D. How platelets safeguard vascular integrity. J Thromb Haemost 2011, 9, 56–65. [Google Scholar] [CrossRef]
  72. Halucha, K.; Rak-Pasikowska, A.; Bil-Lula, I. Protective Role of Platelets in Myocardial Infarction and Ischemia/Reperfusion Injury. Cardiol Res Pract 2021, 2021, 5545416. [Google Scholar] [CrossRef] [PubMed]
  73. Ledent, C.; Vaugeois, J.M.; Schiffmann, S.N.; Pedrazzini, T.; El Yacoubi, M.; Vanderhaeghen, J.J.; Costentin, J.; Heath, J.K.; Vassart, G.; Parmentier, M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997, 388, 674–678. [Google Scholar] [CrossRef]
  74. Yang, D.; Chen, H.; Koupenova, M.; Carroll, S.H.; Eliades, A.; Freedman, J.E.; Toselli, P.; Ravid, K. A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 2010, 8, 817–827. [Google Scholar] [CrossRef]
  75. Johnston-Cox, H.A.; Ravid, K. Adenosine and blood platelets. Purinergic Signal 2011, 7, 357–365. [Google Scholar] [CrossRef]
  76. Fernández-Dueñas, V.; Gómez-Soler, M.; López-Cano, M.; Taura, J.J.; Ledent, C.; Watanabe, M.; Jacobson, K.A.; Vilardaga, J.P.; Ciruela, F. Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism. ACS Chem Biol 2014, 9, 2496–2501. [Google Scholar] [CrossRef] [PubMed]
  77. Ammaturo, V.; Perricone, C.; Canazio, A.; Ripaldi, M.; Ruggiano, A.; Zuccarelli, B.; Monti, M. Caffeine stimulates in vivo platelet reactivity. Acta Med Scand 1988, 224, 245–247. [Google Scholar] [CrossRef]
  78. Ardlie, N.G.; Glew, G.; Schultz, B.G.; Schwartz, C.J. Inhibition and reversal of platelet aggregation by methyl xanthines. Thrombosis and Haemostasis 1967, 18, 670–673. [Google Scholar] [CrossRef]
  79. Bhaskar, S.; Rauf, A.A. Modulatory effect of coffee on platelet function. Indian J Physiol Pharmacol 2010, 54, 141–148. [Google Scholar] [PubMed]
  80. Bydlowski, S.P.; Yunker, R.L.; Rymaszewski, Z.; Subbiah, M.T. Coffee extracts inhibit platelet aggregation in vivo and in vitro. Int J Vitam Nutr Res 1987, 57, 217–223. [Google Scholar] [PubMed]
  81. Bygdeman, S.; Johnsen, O. Methyl xantines in the inhibition of platelet aggregation. Acta Med Scand Suppl 1971, 525, 179–182. [Google Scholar] [CrossRef] [PubMed]
  82. Cavalcante, J.W.; Santos PRJr Menezes, M.G.; Marques, H.O.; Cavalcante, L.P.; Pacheco, W.S. Influence of caffeine on blood pressure and platelet aggregation. Arq Bras Cardiol 2000, 75, 97–105. [Google Scholar] [CrossRef] [PubMed]
  83. Galli, C.; Colli, S.; Gianfranceschi, G.; Maderna, P.; Petroni, A.; Tremoli, E.; Marinovich, M.; Sirtori, C.R. Acute effects of ethanol, caffeine, or both on platelet aggregation, thromboxane formation, and plasma-free fatty acids in normal subjects. Drug Nutr Interact 1984, 3, 61–67. [Google Scholar] [PubMed]
  84. Monti, M.; Edvinsson, L.; Ranklev, E.; Fletcher, R. Methylxanthines reduce in vitro human overall platelet metabolism as measured by microcalorimetry. Acta Med Scand 1986, 220, 185–188. [Google Scholar] [CrossRef]
  85. Naito, S.; Yatagai, C.; Maruyama, M.; Sumi, H. Effect of coffee extracts on plasma fibrinolysis and platelet aggregation. Nihon Arukoru Yakubutsu Igakkai Zasshi 2011, 46, 260–269. [Google Scholar]
  86. Natella, F.; Nardini, M.; Belelli, F.; Pignatelli, P.; Di Santo, S.; Ghiselli, A.; Violi, F.; Scaccini, C. Effect of coffee drinking on platelets: inhibition of aggregation and phenols incorporation. Br J Nutr 2008, 100, 100,1276–1282. [Google Scholar] [CrossRef] [PubMed]
  87. Choi, J.W. Influence of caffeine on the responsiveness of human platelet to agonists. Thromb Res 2003, 110, 209–212. [Google Scholar] [CrossRef] [PubMed]
  88. Montoya, G.A.; Bakuradze, T.; Eirich, M.; Erk, T.; Baum, M.; Habermeyer, M.; Eisenbrand, G.; Richling, E. Modulation of 3',5'-cyclic AMP homeostasis in human platelets by coffee and individual coffee constituents. Br J Nutr 2014, 112, 1427–1437. [Google Scholar] [CrossRef] [PubMed]
  89. Biaggioni, I.; Paul, S.; Puckett, A.; Arzubiaga, C. Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 1991, 258, 588–593. [Google Scholar] [PubMed]
  90. Varani, K.; Portaluppi, F.; Merighi, S.; Ongini, E.; Belardinelli, L.; Borea, P.A. Caffeine alters A2A adenosine receptors and their function in human platelets. Circulation 1999, 99, 2499–2502. [Google Scholar] [CrossRef] [PubMed]
  91. Varani, K.; Portaluppi, F.; Merighi, S.; Ongini, E.; Belardinelli, L.; Borea, P.A. Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects. Circulation 2000, 102, 285–289. [Google Scholar] [CrossRef] [PubMed]
  92. Boncler, M.; Wzorek, J.; Wolska, N.; Polak, D.; Watala, C.; Rozalski, M. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y12 antagonists. Vascul Pharmacol 2019, 113, 47–56. [Google Scholar] [CrossRef]
  93. Wolska, N.; Kassassir, H.; Luzak, B.; Watala, C.; Rozalski, M. Adenosine Receptor Agonists Increase the Inhibition of Platelet Function by P2Y(12) Antagonists in a cAMP- and Calcium-Dependent Manner. Pharmaceuticals (Basel) 2020, 13, 177. [Google Scholar] [CrossRef] [PubMed]
  94. Wolska, N.; Boncler, M.; Polak, D.; Wzorek, J.; Przygodzki, T.; Gapinska, M.; Watala, C.; Rozalski, M. Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y(12) Receptor Antagonists. Molecules 2019, 25, 130. [Google Scholar] [CrossRef]
  95. Polak, D.; Talar, M.; Wolska, N.; Wojkowska, D.W.; Karolczak, K.; Kramkowski, K.; Bonda, T.A.; Watala, C.; Przygodzki, T. Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus. Int J Mol Sci 2021, 22, 3074. [Google Scholar] [CrossRef]
  96. Albino, L.; Sordi, R.; de Oliveira, G., Jr.; Daniel, F. Dose and Time-Dependent Effects of Caffeine on Cardiovascular Changes Induced by Adenosine. Brazilian Archives of Biology and Technology 2023, 66. [Google Scholar] [CrossRef]
  97. Alencar, A.K.N.; Montes, G.C.; Barreiro, E.J.; Sudo, R.T.; Zapata-Sudo, G. Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Front Pharmacol 2017, 8, 858. [Google Scholar] [CrossRef] [PubMed]
  98. Mcguire, M. Caffeine in Food and Dietary Supplements: Examining Safety: Workshop Summary. In Advances in nutrition (Bethesda, Md.); The National Academies Press: Washington, DC, USA, 2014; Volume 5, pp. 585–586. [Google Scholar]
  99. Ponnoth, D.S.; Sanjani, M.S.; Ledent, C.; Roush, K.; Krahn, T.; Mustafa, S.J. Absence of adenosine-mediated aortic relaxation in A(2A) adenosine receptor knockout mice. Am J Physiol Heart Circ Physiol 2009, 297, H1655–H1660. [Google Scholar] [CrossRef] [PubMed]
  100. Geleijnse, J.M. Habitual coffee consumption and blood pressure: An epidemiological perspective. Vasc Health Risk Manag 2008, 4, 963–970. [Google Scholar] [CrossRef]
  101. Mesas, A.E.; Leon-Muñoz, L.M.; Rodriguez-Artalejo, F.; Lopez-Garcia, E. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. Am J Clin Nutr 2011, 94, 1113–1126. [Google Scholar] [CrossRef] [PubMed]
  102. Geethavani, G.; Rameswarudu, M.; Rameshwari, R.R. Effect of Caffeine on Heart Rate and Blood Pressure. International Journal of Scientific and Research Publications 2014, 4, 1–2. [Google Scholar]
  103. Mahmud, A.; Feely, J. Acute Effect of Caffeine on Arterial Stiffness and Aortic Pressure Waveform. Hypertension 2001, 8, 227–231. [Google Scholar] [CrossRef] [PubMed]
  104. Echeverri, D.; Montes, F.R.; Cabrera, M.; Galán, A.; Prieto, A. Caffeine's Vascular Mechanisms of Action. Int J Vasc Med 2010, 2010, 834060. [Google Scholar] [CrossRef]
  105. Vlachopoulos, C.; Panagiotakos, D.; Ioakeimidis, N.; Dima, I.; Stefanadis, C. Chronic coffee consumption has a detrimental effect on aortic stiffness and wave reflections. Am J Clin Nutr 2005, 81, 1307–1312. [Google Scholar] [CrossRef]
  106. Papaioannou, T.G.; Karatzi, K.; Karatzis, E.; Papamichael, C.; Lekakis, J.P. Acute effects of caffeine on arterial stiffness, wave reflections, and central aortic pressures. Am J Hypertens 2005, 18, 129–136. [Google Scholar] [CrossRef]
  107. Echeverri, D.; Pizano, A.; Montes, F.R.; Forcada, P. Acute effect of coffee consumption on arterial stiffness, evaluated using an oscillometric method. Artery Research 2017, 17, 16–32. [Google Scholar] [CrossRef]
  108. Li, P.; Mandilaras, G.; Jakob, A.; Dalla-Pozza, R.; Haas, N.A.; Oberhoffer, F.S. Energy Drinks and Their Acute Effects on Arterial Stiffness in Healthy Children and Teenagers: A Randomized Trial. J Clin Med 2022, 11, 2087. [Google Scholar] [CrossRef] [PubMed]
  109. Mendoza, M.F.; Sulague, R.M.; Posas-Mendoza, T.; Lavie, C.J. Impact of Coffee Consumption on Cardiovascular Health. Ochsner J 2023, 23, 152–158. [Google Scholar] [CrossRef] [PubMed]
  110. Turnbull, D.; Rodricks, J.V.; Mariano, G.F.; Chowdhury, F. Caffeine and cardiovascular health. Regul Toxicol Pharmacol 2017, 89, 165–185. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

157

Views

97

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2025 MDPI (Basel, Switzerland) unless otherwise stated